Theravance Biopharma, INC Form 4 insider transactions

Theravance Biopharma Director Eran Broshy sold 59,000 ordinary shares and exercised 14,000 stock options on November 11, 2025, under a pre-arranged trading plan.

Theravance Biopharma CEO Rick Winningham disposed of 15,394 ordinary shares to cover tax obligations from restricted stock unit vesting.

Theravance Biopharma's SVP & CFO, Aziz Sawaf, disposed of 9,368 ordinary shares at $13.39 each to cover tax liabilities from restricted stock unit vesting.

Aine Miller, SVP at Theravance Biopharma, disposed of 6,989 ordinary shares to cover tax obligations from restricted stock unit vesting.

A Theravance Biopharma executive disposed of shares to cover tax obligations from restricted stock unit vesting.

A Theravance Biopharma executive reported a future disposition of shares to cover tax obligations related to restricted stock unit vesting.

A senior executive at Theravance Biopharma, Inc. sold 10,000 ordinary shares for approximately $11.39 per share, executed under a pre-existing 10b5-1 trading plan.

Theravance Biopharma, Inc. CEO Rick E. Winningham reported gifting 20,000 ordinary shares, a transaction filed with the SEC on June 25, 2025.

Theravance Biopharma CEO Rick E. Winningham reported gifting 9,600 ordinary shares to a custodial account for his grandchildren, disclaiming beneficial ownership of these shares.

Rhonda Farnum, SVP of Commercial and Medical Affairs at Theravance Biopharma, Inc., sold 24,000 ordinary shares for $11 per share, as part of a pre-arranged 10b5-1 trading plan.

CEO Rick Winningham of Theravance Biopharma reports disposing of shares to cover tax obligations related to vesting restricted stock units.

Aziz Sawaf, SVP & CFO of Theravance Biopharma, disposed of 9,348 ordinary shares to cover tax obligations arising from vesting restricted stock units.

Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc., reports disposing of 9,743 ordinary shares to cover tax obligations related to vesting restricted stock units.

Rhonda Farnum, SVP at Theravance Biopharma, reports disposing of 9,120 ordinary shares to cover tax obligations arising from vesting restricted stock units.

Aine Miller, SVP at Theravance Biopharma, reports acquisition of 10,430 shares via RSU vesting and disposition of 9,701 shares to cover tax obligations.

Director Deepika Pakianathan reports the acquisition of stock options and disposal of ordinary shares in Theravance Biopharma.

Director Donal O'Connor reports acquisition of shares and options in Theravance Biopharma, Inc.

Dean J. Mitchell, a director of Theravance Biopharma, acquired shares and options in a transaction dated May 19, 2025.

Director Susannah Gray reports acquisition of Theravance Biopharma shares and options, signaling potential confidence in the company's future.

Director Jeremy T. Grant reports acquisition of share options and disposal of ordinary shares in Theravance Biopharma, Inc.

Director Eran Broshy reports acquisition of shares and options in Theravance Biopharma.

Director Laurie Smaldone Alsup reports acquisition of Theravance Biopharma shares and options, signaling potential confidence in the company's future.

Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, sold 4,000 ordinary shares at $9 per share on April 21, 2025, according to a Form 4 filing.

Rick E. Winningham, CEO of Theravance Biopharma, acquired 2,178 ordinary shares at $9.35 per share under the company's equity incentive plan.

Aziz Sawaf, CFO of Theravance Biopharma, reports acquiring 75,000 ordinary shares on February 28, 2025.

Aine Miller, SVP at Theravance Biopharma, reports acquiring 75,000 ordinary shares on February 28, 2025.

Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc., acquired 75,000 ordinary shares on February 28, 2025.

Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, acquired 75,000 ordinary shares on February 28, 2025.

Rick Winningham, CEO of Theravance Biopharma, reports the disposal of shares to cover tax obligations related to vesting restricted stock units.

Aziz Sawaf, CFO of Theravance Biopharma, disposed of shares to cover tax obligations related to vesting restricted stock units.